Use the hyperlinks, where available to access additional clinical trial information.
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy
This is a randomised, open-label trial with three active comparator arms each evaluating different dose levels of axatilimab. Participants in Active Comparator Arm 1 will receive axatilimab via intravenous infusions (IV) at a dose of 0.3mg/kg Q2W. Participants in Active Comparator Arm 2 will receive axatilimab via IV at a dose of 1mg/kg Q2W. Participants in Active Comparator Arm 3 will receive axatilimab via IV at a dose of 3mg/kg Q4W.